Creatv MicroTech, Inc.

Creatv MicroTech has two divisions: Creatv Bio and Microfabrication. The company is most focused on Creatv Bio Division, and its mission is to dramatically reduce global cancer mortality. Our innovative LifeTracDx® blood test can detect cancer in the earliest stages before symptoms. It can also confirm whether a patient is responding to treatment and surveils for early signs of recurrence after treatment has finished. Creatv Bio also developed a wide spectrum of cancer diagnostics to improve patient care. Clinical application of this highly sensitive and specific test will improve cancer treatment outcomes. Cancer touches all of us. Almost 40% of Americans develop cancer in their lifetime. Over half of these diagnoses occur after significant progression, in stages 3 and 4, making it difficult to achieve successful therapeutic outcomes. Early detection with high accuracy is needed for all major cancers. Nearly 18 million Americans are living with a history of cancer, many in remission under surveillance for possible recurrence. Early detection of recurrence enables faster response and improved outcomes. LifeTracDx® liquid biopsy platform uncovered a previously unknown cell in the blood of cancer patients, the cancer associated macrophage-like cell (CAML). These cells are very large and distinctly different from normal cells and circulating tumor cells (CTCs). CAMLs are found in patients with cancer, but not in healthy individuals. CAMLs are highly informative, because they contain markers of the cancer type and indicate sensitivity or resistance to particular treatments. Unlike CTCs, CAMLs are found in all stages of cancer, including stage I. Together, CAMLs and CTCs provide a unique capability for early detection of cancer, monitoring treatment, and watching for recurrence. LifeTracDx® will be available in a CLIA lab by the beginning of the second quarter of 2025.